TARA
Protara Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TARA
Protara Therapeutics, Inc.
A biopharmaceutical company that developing translational therapies for patients with rare and specific diseases
Biological Technology
03/24/2006
10/22/2014
NASDAQ Stock Exchange
28
12-31
Common stock
345 Park Avenue South, 3rd Floor, New York, NY 10010
--
Protara Therapeutics, Inc., was originally incorporated in Delaware on March 24, 2006. The company is a clinical-stage biopharmaceutical company based in New York City that advances transformative therapies for the treatment of cancer and rare diseases. The company's product portfolio includes two development projects utilizing TARA-002, an investigational cell therapy based on the broad immune-enhancing agent OK-432, which was originally granted marketing authorization by the Ministry of Health and Welfare of Japan as an immune-enhancing cancer treatment agent.
Company Financials
EPS
TARA has released its 2025 Q3 earnings. EPS was reported at -0.31, versus the expected -0.38, beating expectations. The chart below visualizes how TARA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
